tbuckley/cabot-search huggingface dataset:
POS1460 MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN’S SYNDROME
Authors: K. Chandwar, D. P. Misra, K. Kishor, P. Dogga, D. Ekbote, J. Dixit, A. Wakhlu, V. Agarwal, A. Wakhlu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background:</h3> <h3>Objectives</h3> To assess major salivary gland involvement by ultrasonography and elastography in patients with Primary Sjögren's syndrome (pSS), correlate the severity of ultrasonographic and elastographic involvement of major salivary gland with disease activity. <h3>Methods</h3> In 54 pSS patients, disease activity was assessed by the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). The Salivary gland were assessed using the Hocevar and OMERACT score and Real time Elastography was performed for the salivary glands and were scored semiquantitatively. <h3>Results</h3> 54 patients of primary Sjögren's Syndrome and 55 controls were included in the study. The patients were younger with a mean age of 37.61±11.56 years (Refer to Figure 1 for demographic and clinical data of pSS patients in the study). Mean USG/Elastography scores were significantly higher (p &lt; 0.001) in cases than controls. ESSDAI correlated strongly with Hocevar Score and OMERACT and Moderately with Elastography. ESSPRI correlated well with Hocevar Score and OMERACT score but poorly with Elastography. All the scores differentiated sufficiently between high and activity efficiently (p&lt;0.001), however, for the OMERACT(p-0.13) and Elastography score(p-0.083) the difference between moderate and low disease activity was not statistically significant. A multivariate linear regression analysis found an association with USG Scores with ESSDAI and ESSPRI, Elastography with ESSDAI and Disease duration. <h3>Conclusion</h3> The Hocevar score had a robust correlation with disease activity. The Elastography scores moderately correlated with disease activity and duration of disease. There was a near-complete correlation of USG scores with Unilateral, Parotid, and submandibular scores. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1501 LUPUSNET – A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: J. Schreiber, M. Van Speybroeck, F. Zazzetti, W. Noel, T. A. Simon, F. Lavie
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need. Real-world data on SLE are available and currently scattered across more than 50 registries worldwide. The Lupus Federated Data Network (LupusNet) is an interdisciplinary initiative that aims to standardize data and harmonize methodology to create a large, global SLE database from existing registries. <h3>Objectives</h3> This initiative will allow the analysis of real-world data across lupus registries worldwide. <h3>Methods</h3> The central paradigm of LupusNet is a federated model whereby the data reside with the respective registries/data owners and analyses are executed at the local center. As data from different sources have different infrastructures, the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) will be used to standardize data into a common format. Standardization will reduce the heterogeneity in data structure and semantics, allowing for uniform data analysis, collaborative research, large-scale analytics, and sharing of sophisticated tools and methodologies. LupusNet will include prospective, observational registries designed to capture real-world data on demographics, treatments, and outcomes in patients with SLE. Other data, including data originating from randomized clinical trials, will also be part of this initiative. <h3>Results</h3> Currently, 6 registries representing 4 regions of the globe and ~30,000 lupus patients are engaged at the start of this initiative. Examples of the types of data from each registry that are available for standardization and harmonization in LupusNet are shown in <b>Figure 1</b>. Other lupus registries that may be interested in participating in this initiative should contact the authors. Participating registries are not required to collect all types of data to be included in the initiative. Contact the LupusNet team at www.lupusnet.org. <h3>Conclusion</h3> Through the standardization of global registry data, LupusNet hopes to demonstrate the potential of real-world evidence to answer important questions related to SLE with the ultimate goal of improving patient outcomes. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Joerg Schreiber Shareholder of: Johnson &amp; Johnson, Employee of: Janssen-Cilag, Neuss, Germany, Michel van Speybroeck Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Pharmaceutica, Beerse, Belgium, Federico Zazzetti Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Medical Affairs Global Services, LLC, Wim Noel Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Pharmaceutica, Beerse, Belgium, Teresa A. Simon: None declared, Frederic Lavie Shareholder of: Johnson &amp; Johnson, Employee of: The Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Paris, France.
POS1465 ASSOCIATION OF COMPLEMENT ACTIVATION AND TNFΑ WITH PREGNANCY PROGNOSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME
Authors: A. Isik, S. Çinar, S. Onder, A. Bayram, E. Yavuz, T. Sarac Sivrikoz, I. Kalelioglu, C. Cetin, Y. Yalçinkaya, A. Gul, M. Inanc, B. Artim-Esen
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Complement activation is associated with adverse pregnancy outcomes in in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). TNFα is accused in the etiology of impaired placenta development and preeclampsia. <h3>Objectives</h3> We aimed to investigate the association of complement(c) activation and TNFα with poor pregnancy outcomes in patients with SLE/APS. <h3>Methods</h3> Four groups were examined: pregnant SLE/APS (n=37), non-pregnant SLE/APS(n=15), healthy pregnant (n=20) and healthy women (n=14). C3b, C5a and TNFα were tested by ELISA in the serum (s) samples taken at the last trimester of each pregnancy. Collected placental tissues were examined histopathologically and were stained for TNFα and C4d. <h3>Results</h3> sC3b levels and positivity rates were higher in pregnant SLE/APS compared to all other groups (p&lt;0.05 for all). Pregnancy loss (18,9%) and preeclempsia (16,2%) were the most common pregnancy morbidities. Renal (30,5%) followed by hematologic (thrombocytopenia) (19,4%) were the most common flares in pregnant patients with SLE/APS and compared to patients without, they had significantly higher sTNFα levels (p&lt;0,05). The frequency of sTNFα positivity were significantly higher in SLE/APS patients with preeclampsia (p&lt;0.05). Sixty-six % of SLE/APS placentas had C4d deposition whilst none of the healthies were stained (p &lt;0,001). Frequency of strong staning with TNFα in SLE/APS (75,8%) was significantly higher compared to healthy placentas (27,8%)(p&lt;0,001). Decidual vasculopathy, decidual inflammation and villous infarction were significantly more frequent in SLE/APS (Table 1). Significant associations were found between these findings and preeclampsia, intrauterine growth retardation and the need for neonatal intensive care (p&lt;0,001). <h3>Conclusion</h3> Results of our study shows TNFα and complement activation both at tissue level and serum, and supports their association with adverse pregnancy outcome in SLE/APS.Further work is necessary to test whether these biomarkers can be used for follow up and to explore whether TNFα and complement directed therapies may improve maternal/fetal prognosis in patients with SLE/APS. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1400-HPR COMPARISON OF BODY AWARENESS, PHYSICAL ACTIVITY, KINESIOPHOBIA, PAIN CATASTROPHIZING, AND PSYCHOSOCIAL STATUS IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
Authors: G. I. Kinikli, N. B. Karaca, S. Sezer, B. Keleşoğlu, G. Kinikli
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are among the most common rheumatic (joint) conditions. RA and AS are different types of arthritis. Living with RA or AS can significantly affect your quality of life, mental health, and emotional well-being. <h3>Objectives</h3> We report the preliminary results of an ongoing prospective observational study that compare the body awareness, physical activity, kinesiophobia, pain catastrophizing and psychosocial status in individuals with RA and AS. <h3>Methods</h3> A total of 78 individuals (RA=48; AS=30; women/men=48/30) recruited from two university hospitals in Turkey. All individuals were assessed regarding physical characteristics (age, BMI, duration of disease, BASDAI, DAS-28); body awareness by Body Awareness Questionnaire, physical activity level by International Physical Activity Questionnaire Short Form, fear of movement by Tampa Scale of Kinesiophobia, pain catastrophizing by Pain Catastrophizing Scale and psychosocial status by Beck Depression Inventory. <h3>Results</h3> Individuals' characteristics and outcome measures are presented in Table 1. As expected, there were statistical differences between age and gender in study groups (p&lt;0.001). However, disease duration and disease activity, mild depression level were similar between groups. Individuals with AS were significantly more physically active compared to individuals with RA (p&lt;0.005). Body awareness, kinesiophobia, pain catastrophizing and psychosocial status were similar between groups (p&gt;0.05). In addition, disease activity was moderately correlated with body awareness, pain catastrophizing and kinesiophobia individuals with AS (r=-0.529; r=0.613; r=0.427, p&lt;0.05). <h3>Conclusion</h3> Treatment of RA and AS is similar, but there are key differences. According to our results, individuals with AS is more physically active than individuals with RA regardless of disease duration and disease activity. Health professionals can also focus on correlation between disease activity and higher body awareness, pain catastrophizing and kinesiophobia in individuals with AS. <h3>References</h3> [1]Oskay D, Tuna Z, Düzgün İ, Elbasan B, Yakut Y, Tufan A. Relationship between kinesiophobia and pain, quality of life, functional status, disease activity, mobility, and depression in patients with ankylosing spondylitis. Turk J Med Sci. 2017 Nov 13;47(5):1340-1347. doi: 10.3906/sag-1702-93. PMID: 29151302. [2]Baday-Keskin D, Ekinci B. The relationship between kinesiophobia and health-related quality of life in patients with rheumatoid arthritis: A controlled cross-sectional study. Joint Bone Spine. 2022 Mar;89(2):105275. doi: 10.1016/j.jbspin.2021.105275. Epub 2021 Sep 15. PMID: 34536623. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1487 CLINICAL SIGNIFICANCE OF DIFFERENT PROFILES OF ANTI-Ro ANTIBODIES IN CONNECTIVE TISSUE DISEASES
Authors: Y. Chen, H. T. Yang, D. Liu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs) <sup>[1]</sup>. However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. <h3>Objectives</h3> To investigate the clinical characteristics of patients with anti-Ro antibodies. <h3>Methods</h3> A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies. <h3>Results</h3> Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren's syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, <i>p</i>=0.029) (<b>Figure 1</b>). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs.11.3% vs.13.7%, <i>p</i>&lt;0.0001) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, <i>p</i>=0.001) compared with the other two groups of patients (<b>Table 1</b>). Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies. <h3>Conclusion</h3> Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice. <h3>Reference</h3> [1]Lee A Y S, J H Reed, and T P Gordon. Anti-Ro60 and anti-Ro52/TRIM21: Two distinct autoantibodies in systemic autoimmune diseases. J Autoimmun, 2021 Nov;124:102724. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1486 RELATIONSHIP BETWEEN THE EULAR/ACR CLASSIFICATION CRITERIA AND ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: C. C. Mok, Y. K. Chung, C. Lee, L. Y. Ho, C. H. To
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background:</h3> <h3>Objectives</h3> To study the relationship between the 2019 EULAR/ACR classification criteria and organ damage in patients with systemic lupus erythematosus (SLE) <h3>Methods</h3> Patients involved in a cross-sectional validation study of the EULAR/ACR criteria and judged by a panel of rheumatologists to be clinical SLE were studied. Those who fulfilled the EULAR/ACR criteria at their last clinic visit were stratified into 2 groups based on a cut-off score of 20. The last SLE international collaborating clinic (SLICC) organ damage index (SDI) was compared between these two groups. Relationship among the domains of the EULAR/ACR criteria and SDI in all patients was studied by Spearman's rank correlation. <h3>Results</h3> 562 SLE patients were studied (93.6% women; age 36.5±14.1 years; follow-up duration 11.6±6.6 years). The mean and median EULAR/ACR criteria scores in those who fulfilled the EULAR/ACR criteria (N=542) was 24.6±7.3 and 24 (interquartile range 19-30), respectively. A total of 392 patients had EULAR/ACR scores of ≥20 (group 1) and 150 patients had scores of 10-19 (group 2). Group 1 patients had significantly higher prevalence of fever, alopecia, oral ulcers, acute lupus skin lesions, arthritis, serositis, seizure, hemolytic anemia, leukopenia and renal disease, and so were the anti-dsDNA, anti-Sm, antiphospholipid antibodies and low complement state. Organ damage (SDI score of ≥1) occurred in 232 (42.8%) patients. Patients in group 1 had significantly higher SDI scores in the renal, cardiovascular, dermatological and gonadal domains than group 2. The renal, neuropsychiatric and antiphospholipid antibodies domain scores of the EULAR/ACR criteria correlated positively with the total SDI. The renal domain of the EULAR/ACR criteria had the strongest correlation with renal damage (Rho 0.30; p&lt;0.001). Patients who scored 10 points in the renal domain had significantly higher renal damage score than those scored 8 points or 4 points. Gonadal damage score was also significantly more common in the 10-point than 8-point group. <h3>Conclusion</h3> In addition to disease classification, the EULAR/ACR SLE criteria may have a role in predicting organ damage and disease prognosis. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1496 THE AUTOANTIBODY FOR BETA-2-GLYCOPROTEIN I COMPLEXED WITH HLA-DR LINKED TO ARTERIAL THROMBOSIS IN FEMALE PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES
Authors: K. Yoneda, Y. Ueda, H. Yamada, K. Nishimura, S. Sendo, K. Tanimura, H. Arase, H. Yamada, J. Saegusa
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Beta-2-glycoprotein I complexed with HLA-DR molecules (β2GPI/HLA-DR) was found to be a major autoantibody target in APS. <h3>Objectives</h3> We aim to reveal the association between anti-β2GPI/HLA-DR antibodies and vascular thrombosis or obstetric morbidities in females with various systemic rheumatic diseases. <h3>Methods</h3> This was a single-center, retrospective longitudinal study of female patients in our center from 2020 to 2021. Clinical and laboratory data were retrieved from medical records and questionnaires. Anti-β2GPI/HLA-DR antibody was compared with the risk score reported as an adjusted global APS score (aGAPSS). The optimal cutoff value was calculated using receiver operating characteristic (ROC) analysis to detect arterial thrombosis. Finally, we assessed the impact of anti-β2GPI/HLA-DR antibodies on arterial thrombosis in addition to the conventional risk model with multivariable logistic regression analysis. <h3>Results</h3> We evaluated 704 patients, including 66 (obstetric or thrombotic) APS, 13 primary APS, and 78 asymptomatic aPL carriers, that comorbid 260 Systemic Lupus Erythematosus (SLE) or Mixed Connective tissue diseases (MCTD). Seventy-seven patients had one or more histories of arterial thrombosis, and 14 patients of them had a history of both arterial and venous thrombosis. The titers were significantly higher in patients with arterial and venous thrombosis than in those without thrombosis. In cases with aGAPSS&gt;10 or triple positive aPL, the titers tended to be higher. The ROC showed that the sensitivity, specificity, and area under the curve (AUC) for arterial thrombosis were 33.8%, 91.4%, and 0.60 with a cutoff value of 172.359 U/ml. By the multivariable logistic regression analysis with multiple imputation, the odds ratio of anti-β2GPI/HLA-DR antibody ≧172.359 was 5.11(95% confidence interval: 2.84-9.19; P&lt;0.001) (Table 1). When adding the cutoff value to conventional cardiovascular risk factors improved the AUC from 0.677 to 0.730 (p = 0.088). Determined net reclassification improvement and integrated discrimination improvement were statistically significant (Figure 1). <h3>Conclusion</h3> Anti-β2GPI/HLA-DR antibody is associated with arterial thrombosis in females with various systemic rheumatic diseases. <h3>References</h3> [1] Blood. 2015;125(18):2835-2844. [2] Arthritis Rheumatol. 2020;72(11):1882-1891. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Katsuhiko Yoneda: None declared, Yo Ueda: None declared, Hirotaka Yamada: None declared, Keisuke Nishimura: None declared, Sho Sendo Speakers bureau: Abbvie, Chugai, Kenji Tanimura: None declared, Hisashi Arase: None declared, Hideto Yamada: None declared, Jun Saegusa: None declared.
POS1495 LOW INTENSITY OF C1Q DEPOSITION WITH RENAL IMMUNOFLUORESCENCE PREDICTS LONG-TERM POOR RENAL PROGNOSIS IN LUPUS NEPHRITIS
Authors: K. Hiramoto, H. Hanaoka, K. Saito, H. Fukui, J. Kikuchi, S. Saito, Y. Kaneko
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Although the prognosis of lupus nephritis (LN) has been improved due to recent advances in diagnosis and treatment, its long-term renal outcome is still poor. In spite of previous studies that investigated a number of prognostic factors, association of long-term renal outcome with renal histological findings focusing on immunofluorescence has been little elucidated. <h3>Objectives</h3> To clarify renal histological and immunofluorescent findings associated with deterioration of renal function in LN. <h3>Methods</h3> Consecutive patients with biopsy-proven LN class III/IV/V from 2008 to 2017 in our hospital were included in the study. They were classified into two groups: patients with deterioration of renal function and those without. The deterioration of renal function was defined as more than 30% decline in estimated glomerular filtration rate (eGFR) from baseline. Clinical characteristics and renal histological findings with immunofluorescence at the time of LN diagnosis were compared between the two groups. <h3>Results</h3> Sixty-nine patients (class III/IV 34; class III/IV+V 21; class V 14) were included in the analysis. Renal function was deteriorated during 5 years observation in 12 patient (17.4%). There was no significant difference in age (48 vs 42 years, p=0.16), disease duration (11.4 vs 9.8 years, p=0.65), and urinary protein-to-creatinine ratio (2.3 vs 2.2 g/gCr, p=0.56) between the deterioration and non-deterioration groups. The treatment regimens including maximum prednisolone dose (41 vs 47 mg/day, p=0.14), cyclophosphamide use (42 vs 54%, p=0.53) and mycophenolate mofetil use (0 vs 24%, p=0.11) were also not different. Regarding renal histopathological findings, while proportion of III/IV class (83 vs 79%, p=1.00), activity index (1 vs 4, p=0.14), and chronicity index (4 vs 3, p=0.19) were not different between the two groups, intensity of C1q deposition in renal immunofluorescence was significantly weaker in the deterioration group than the non-deterioration group; proportion of C1q deposition in renal immunofluorescence ≤ 1+ was 100% in the deterioration group compared to 47% in the non-deterioration group (p=0.006). When we divided the patients according to the intensity of C1q deposition, the cumulative deterioration rates of renal function were significantly different (p=0.01, Figure 1). The patients with low intensity of C1q deposition (≤ 1) had a lower positivity of serum anti-dsDNA antibody (75 vs 96%, p=0.04) and a higher serum C3 levels (54 vs 40 mg/dl, p=0.03) at LN diagnosis. Anti-SSA antibodies tended to be higher in the deterioration group than the non-deterioration group (80 vs 64%, p=0.43). <h3>Conclusion</h3> Low C1q deposition in renal immunofluorescence at LN diagnosis is associated with poor renal prognosis in LN. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.